<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Document</title>
    <link rel="preconnect" href="https://fonts.googleapis.com">
<link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
<link href="https://fonts.googleapis.com/css2?family=Montserrat:ital,wght@0,100..900;1,100..900&display=swap" rel="stylesheet">

</head>
<link rel="stylesheet" href="style.css">
<body>
           <ul><li>
            <li><h5 class="font1">CORRESPONDENCE</h5></li>
            <li>|</li>
            <li ><h5>NOV 13,2024</h5></li>
            <li>|</li>
            <li><h5 class="FREE">FREE</h5></li>
  
           </li></ul>
    <img class="image" src="./image/chart.png
    " alt="">
    <p class="Text">
        <b>
            Activity of Research-Grade 
            Pemivibart againts SARS-CoV-2 
            Sublineages
        </b>
    </p>
    <h4>Q. Wang and Others</h4>
    <p class="para"> SARS-CoV-2 continues to evolve under immunologic pressure. 
        A synthesized version of pemivibart, an anti-SARS-CoV-2 monoclonal 
        antibody with recent emergency-use authorization, showed mixed 
        activity againts emerging variants

    </p>
    <p class="para2">
        <b>Correction</b> Pemivibart Activity againts Recent SARS-CoV-2 jN.1 <br>
        Sublineages
    
    </p>


</body>
</html>